

2025/10/14

RIBOMIC Presents Successful Phase II Clinical Trial of Achondroplasia Treatment at The Oligonucleotide Therapeutics Society International Conference

TOKYO, October 14, 2025 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia. The company announced today that an oral presentation reporting the success of the Phase II clinical trial for the achondroplasia treatment drug (umedaptanib pegol) has been accepted for the 21st Annual Meeting of The Oligonucleotide Therapeutics Society ^{OTS} scheduled for October 2025. President and CEO Yoshikazu Nakamura will deliver the presentation.

In addition to the content disclosed on October 8, this presentation will also report efficacy data showing that in two pediatric patients with prior treatment history of the approved drug VOXZOGO® (Vosoritide, manufactured by BioMarin), the height growth velocity improved by +1.1 cm and +2.0 cm/year after administration of umedaptanib pegol.

Date: October 19-22, 2025

Venue: Budapest Congress Center

Title: Anti-FGF2 Aptamer Therapy in Achondroplasia

Date & Time: October 22, 09:10-09:25 am (Session VIII Rare Diseases)

URL: <https://www.2025oligomeeting.com>

We plan to pursue monetization of this project while seeking partners to conduct Phase 3 trials. The final summary of the trial's analysis results is scheduled for March 2026, and detailed data analysis is currently ongoing.

There are no changes to the full-year earnings forecast for the fiscal year ending March 2026.

^{OTS} This is one of the world's largest international conferences in the field of nucleic acid therapeutics, aiming to promote research and development of nucleic acid therapeutics through industry-academia collaboration (<https://www.oligotherapeutics.org>).

RIBOMIC Inc.

ir.inquiry@ribomic.com